Betahistine: what's new on the agenda?

Bibliography

• Löffler K, Kirschner M. Derivate des α-Picolyl-und α-Picolylmethyl-Alkins. Berichte der Deutschen Chemischen Gesellschaft 1905;38:3329-43
   Google Scholar
• Hunt WH, Fosbinder RJ. A Study Of Some Beta-2 And 4 Pyridylalkylamines. J Pharmacol Exp Ther 1942;75:299-307
   Google Scholar
• Walter LA, Hunt WH, Fosbinder RH. β-(2- and 4-Pyridylalkyl)-amines. J Am Chem Soc 1941;63:2768-70
   Google Scholar
• Horton BT, Von Leden H. Clinical use of beta-2-pyridylalkylamines I. Proc Staff Meet Mayo Clin 1962;37:692-702
   PubMed Web of Science ®Google Scholar
• Horton BT. The clinical use of beta-2-pyridylalkylamines. II. Treatment of histaminic cephalgia (Horton's headache) with a note on angina pectoris. Proc Staff Meet Mayo Clin 1962;37:713-23
   PubMed Web of Science ®Google Scholar
• Elia JC. Double-blind evaluation of a new treatment for Meniere's syndrome. JAMA 1966;196:187-9
   PubMed Web of Science ®Google Scholar
• Parsons ME, Ganellin R. Histamine and its receptors. Br J Pharmacol 2006;147:S127-35
   PubMed Web of Science ®Google Scholar
• Wijtmans M, Leurs R, de Esch I. Histamine H 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16:967-85
   PubMed Web of Science ®Google Scholar
• Zhang M, Venable JD, Thurmond RL. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 2006;15:1443-52
   PubMed Web of Science ®Google Scholar
• Fossati A, Barone D, Benvenuti C. “Binding affinity profile of Betahistine and its metabolitesfor central histamine receptors of rodents,”. Pharmacol Res 2001;43:389-92
   PubMed Web of Science ®Google Scholar
• Lacour M, Sterkers O. Histamine and Betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001;15:853-70
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Quach TT, et al. Actions of Betahistine at histamine receptors in the brain. Eur J Pharmacol 1985;111:73-84
   PubMed Web of Science ®Google Scholar
• Snow JB, Suga F. Labyrinthine vasodilators. Acat Otolaryngol 1973;97:365-70
   Google Scholar
• Hunt HW, Fosbinder RJ. A study of some beta 2- and 4, pyridylalkylamines. J Pharmacol Exp Ther 1942;75:299-307
   Google Scholar
• Smith KA, Meyer MW. Distribution of cardiac output in dogs during intravenous infusion of Betahistine. Stroke 1976;7:357-60
   Google Scholar
• Tobia JA, Sternson LA, Walsh JA. The role of desmethylBetahistine in the depressor responses to Betahistine in the rat. Proc Soc Exp Biol Med 1974;145:7778-81
   Google Scholar
• Curwain BP, Holton P, Spencer J. The effect of Betahistine on gastric acid secretion and mucosal blood flow in conscious dogs. Br J Pharmacol 1972;46:351-4
   PubMed Web of Science ®Google Scholar
• van Cauwenberge PB, de Moor SEG. Physiopathology of H3-receptors and pharmacology of betahistine. Acta Otolaryngol 1997;526:43-6
   Google Scholar
• Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991;71:1-51
   PubMed Web of Science ®Google Scholar
• Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121-30
   PubMed Web of Science ®Google Scholar
• Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-72
   PubMed Web of Science ®Google Scholar
• Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels, 2007 revision. Br J Pharmacol 2007;150(Suppl 1):S47
   PubMed Web of Science ®Google Scholar
• Martinez-Mir MI, Pollard H, Moreau J, et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 1990;526:322-7
   PubMed Web of Science ®Google Scholar
• Terao A, Steininger TL, Morairty SR, et al. Age-related changes in histamine receptor mRNA levels in the mouse brain. Neurosci Lett 2004;355:81-4
   PubMed Web of Science ®Google Scholar
• Vizuete ML, Traiffort E, Bouthenet ML, et al. Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain. Neuroscience 1997;80:321-43
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832-7
   PubMed Web of Science ®Google Scholar
• Pollard H, Moreau J, Arrang JM, Schwartz JC. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993;52:169-89
   PubMed Web of Science ®Google Scholar
• Zhang M, Venable JD, Thurmond RL. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 2006;15:1443-52
   PubMed Web of Science ®Google Scholar
• Laurikainen E, Miller JF, Pyykkö I. Betahistine effects on cochlear blood flow: from the laboratory to the clinic. Acta Otolaryngol Suppl 2000;544:5-7
   PubMedGoogle Scholar
• Fanciullacci M. When cluster headache was called histaminic cephalalgia (Horton's headache). Headache Pain 2006;7:231-4
   PubMedGoogle Scholar
• Lovshin LL. Clinical caprices of histaminic cephalalgia. Headache 1961;1:7-10
   PubMedGoogle Scholar
• Horton BT. Histaminic cephalgia (Horton's headache or syndrome). Md State Med J 1961;10:178-203
   PubMedGoogle Scholar
• Capobianco DJ, Dodick DW. Diagnosis and treatment of cluster headache. Semin Neurol 2006;26:242-59
   PubMed Web of Science ®Google Scholar
• Minor LB, Schessel DA, Carey JP. Ménière's disease. Curr Opin Neurol 2004;17:9-16
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Quach TT, et al. An agent for the amelioration of vertigo in Meniere's syndrome. Betahistine hydrochloride (Serc). JAMA 1968;203:1122
   PubMed Web of Science ®Google Scholar
• Smith WK, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. J Laryngol Otol 2005;119:102-5
   PubMed Web of Science ®Google Scholar
• Jeck-Thole S, Wagner W. Betahistine A retrospective synopsis of safety data. Drug Safety 2006;29:1049-59
   PubMed Web of Science ®Google Scholar
• James AL, Burton MJ. Betahistine for Ménière's disease or syndrome. Cochrane Database Syst Rev 2001;1:CD001873
   PubMedGoogle Scholar
• Esser AH, Reis J. Preliminary study of Betahistine in chronic psychiatric patients with symptoms of arterio sclerosis cerebri. Curr Ther Res Clin Exp 1968;10:122-7
   PubMed Web of Science ®Google Scholar
• Meyer JS, Mathew NT, Hartmann A, Rivera VM. Orally administered Betahistine and regional cerebral blood flow in cerebrovascular disease. J Clin Pharmacol 1974;14:280-9
   PubMed Web of Science ®Google Scholar
• Rivera VM, Meyer JS, Baer PE, et al. Vertebrobasilar arterial insufficiency with dementia. Controlled trials of treatment with Betahistine hydrochloride. J Am Geriatr Soc 1974;22:397-406
   PubMed Web of Science ®Google Scholar
• Pathy J, Menon G, Reynolds A, van Strik R. Betahistine hydrochloride (Serc) in cerebrovascular disease: a placebo-controlled study. Age Ageing 1977;6:179-84
   PubMedGoogle Scholar
• Spruill JH, Toole JF, Kitto W, Miller HE. A comparison of Betahistine hydrochloride with placebo for vertebral-basilar insufficiency: a double-blind study. Stroke 1975;6:116-20
   PubMed Web of Science ®Google Scholar
• Hagler WS, Shacklett DE. Use of Betahistine hydrochloride in postoperative retinal detachment patients. Ann Ophthalmol 1971;3:612-6
   PubMedGoogle Scholar
• Bugajski J, Gadek-Michalska A, Bugajski AJ. Nitric oxide and prostaglandin systems in the stimulation of hypothalamic-pituitary-adrenal axis by neurotransmitters and neurohormones. J Physiol Pharmacol 2004;55:679-703
   PubMed Web of Science ®Google Scholar
• Lecklin A, Etu-Seppälä P, Stark H, Tuomisto L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 1998;793:279-88
   PubMed Web of Science ®Google Scholar
• Passani MB, Lin JS, Hancock A, et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618-25
   PubMed Web of Science ®Google Scholar
• Morimoto T, Yamamoto Y, Yamatodani A. Brain histamine and feeding behavior. Behav Brain Res 2001;124:145-50
   PubMed Web of Science ®Google Scholar
• Attoub S, Moizo L, Sobhani I, et al. The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci 2001;69:469-78
   PubMed Web of Science ®Google Scholar
• Masaki T, Chiba S, Yasuda T, et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004;53:2250-60
   PubMed Web of Science ®Google Scholar
• Clineschmidt BV, Lotti VJ. Histamine: intraventricular injection suppresses ingestive behavior of the cat. Arch Int Pharmacodyn Ther 1973;206:288-298
   PubMedGoogle Scholar
• Itowi N, Nagai K, Nakagawa H, et al. Changes in the feeding behavior of rats elicited by histamine infusion. Physiol Behav 1988;44:221-6
   PubMed Web of Science ®Google Scholar
• Orthen-Gambill N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol Biochem Behav 1988;31:81-6
   PubMed Web of Science ®Google Scholar
• Sheiner JB, Morris P, Anderson GH. Food intake suppression by histidine. Pharmacol Biochem Behav 1985;23:721-6
   PubMed Web of Science ®Google Scholar
• Vaziri P, Dang K, Anderson GH. Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J Nutr 1997;127:1519-26
   PubMed Web of Science ®Google Scholar
• Lecklin A, Tuomisto L, MacDonald E. Metoprine, an inhibitor of histamine N-methyltransferase but not catechol-O-methyltransferase, suppresses feeding in sated and in food deprived rats. Methods Find Exp Clin Pharmacol 1995;17:47-52
   PubMed Web of Science ®Google Scholar
• Lecklin A, Tuomisto L. The blockade of H1 receptors attenuates the suppression of feeding and diuresis induced by inhibition of histamine catabolism. Pharmacol Biochem Behav 1998;59:753-8
   PubMed Web of Science ®Google Scholar
• Doi T, Sakata T, Yoshimatsu H, et al. Hypothalamic neuronal histamine regulates feeding circadian rhythm in rats. Brain Res 1994;641:311-8
   PubMed Web of Science ®Google Scholar
• Sakata T, Fukagawa K, Ookuma K, et al. Hypothalamic neuronal histamine modulates ad libitum feeding by rats. Brain Res 1990;537:303-6
   PubMed Web of Science ®Google Scholar
• Orthen-Gambill N, Salomon M. FMH-induced decrease in central histamine levels produces increased feeding and body weight in rats. Physiol Behav 1992;51:891-3
   PubMed Web of Science ®Google Scholar
• Ookuma K, Sakata T, Fukagawa K, et al. Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res 1993;628:235-42
   PubMed Web of Science ®Google Scholar
• Jorgensen EA, Vogelsang TA, Knigge U, et al. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrinology 2006;83:289-94
   PubMed Web of Science ®Google Scholar
• Masaki T, Chiba S, Yasuda T, et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004;53:2250-60
   PubMed Web of Science ®Google Scholar
• Rossi R. Effect of the H1-histamine receptor agonist Betahistine on drinking and eating behavior in pygmy goats. Physiol Behav 1999;66:517-21
   PubMed Web of Science ®Google Scholar
• Szelag A. Betahistine inhibits food intake in rats. Polish J Pharmacol 1999;53:701-7
   Google Scholar
• The effect of betahistine on body weight in obese subjects. Identifier NCT00409305. Available from: www.clinicaltrials.gov
   Google Scholar
• Data on File, Obecure Ltd. Available from: www.obecure.com [Last access date 28 Mar 2008]
   Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatr 2004;65:267
   PubMed Web of Science ®Google Scholar
• Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004;55:151-6
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(Suppl 10):45-9
   PubMed Web of Science ®Google Scholar
• Roerig JL. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol 2005;25:413-8
   PubMed Web of Science ®Google Scholar
• Kroeze WK. H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
   PubMed Web of Science ®Google Scholar
• Wirshing DA. Schizophrenia and obesity, impact of antipsychotic medication. J Clin Psychiatr 2004;65(Suppl 18):13-26
   PubMed Web of Science ®Google Scholar
• Kim SF. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci 2007;104:3456
   PubMed Web of Science ®Google Scholar
• Hendersen DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-62
   PubMed Web of Science ®Google Scholar
• Lin YH. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005;59:613-5
   PubMed Web of Science ®Google Scholar
• Deberdt W. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005;15:13-21
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Levi A, et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005;20:101-3
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Gilad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002;159:1058-60
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004;14:332-6
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160(2):297-302
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Fox GB, Cowart MD. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006;6:77-88
   PubMed Web of Science ®Google Scholar
• Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 2006;101:12-8
   PubMed Web of Science ®Google Scholar
• Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-95
   PubMedGoogle Scholar